Multiply Labs raises $75M; NorthStar secures up to $185M
Multiply Labs closed a $75 million Series B to expand manufacturing capacity and staff for its robotics biomanufacturing business. NorthStar will receive as much as $185 million, and the roundup also covers Genentech and Fresenius Kabi.
The roundup highlights funding activity in drug development and biomanufacturing. Multiply Labs has closed a $75 million Series B round, with plans to grow its production footprint and workforce for robotic biomanufacturing. NorthStar stands to obtain up to $185 million. Genentech and Fresenius Kabi also appear in the same news roundup, though the available material offers no further specifics.
The funding could affect patients who rely on manufactured medicines if expanded robotic biomanufacturing helps improve production capacity or reliability. Biomanufacturing workers may see changing skill requirements. Investors and smaller drug-development firms may read such raises as signals about appetite for manufacturing technology. The mention of Genentech and Fresenius Kabi may indicate broader industry attention, though the available details are limited.